[Form 4] Bio-Techne Corp. Insider Trading Activity

Rhea-AI Filing Summary

James Hippel, Chief Financial Officer of Bio-Techne Corporation (TECH), reported transactions on 08/15/2025. The Form 4 shows a purchase/vest of 4,010 restricted stock units or similar awards (Code M) at $0 and a disposition of 1,926 shares at $53.60 each. After these transactions the reported beneficial ownership of common stock is 129,883 shares. The filing also lists extensive derivative holdings: multiple stock option grants and restricted or performance-based stock units totaling tens of thousands of underlying shares (for example, 186,068, 167,328, 37,632 and other position sizes as detailed in Table II). The form is signed by an attorney-in-fact on behalf of Mr. Hippel.

Positive

• Acquisition/vesting of 4,010 restricted stock units (Code M) increasing direct holdings
• Substantial derivative positions disclosed, including multiple stock option tranches and performance awards aligning executive incentives with long-term performance
• Post-transaction beneficial ownership remains substantial at 129,883 common shares

Negative

• Disposition of 1,926 shares at $53.60 each was executed on 08/15/2025
• Significant portion of compensation is equity-based, including performance-contingent awards subject to future achievement and vesting

Insights

Financial Analyst

TL;DR: Insider received awards and executed a small sale; overall holding remains substantial with multiple option tranches outstanding.

The Form 4 records a non-cash acquisition of 4,010 restricted stock units or similar award (Code M) and a sale of 1,926 common shares at $53.60. The filing confirms large outstanding equity incentives across multiple vesting schedules and strike prices, indicating continued alignment of the CFO with long-term equity compensation. The sale is modest relative to total beneficial ownership and does not, by itself, materially alter his equity stake according to the reported post-transaction balance of 129,883 shares. All positions are reported as direct holdings.

Corporate Governance Expert

TL;DR: Transactions appear routine compensation vesting and a small disposition; disclosure and signing follow Section 16 requirements.

The filing shows customary equity-based compensation events: restricted stock units vesting and numerous option grants with staggered exercisability and performance-based tranches. The use of an attorney-in-fact to sign is documented and appropriate. The Form 4 provides required transparency regarding timing, prices, and post-transaction holdings; no governance or compliance issues are evident from the disclosed entries alone.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hippel James

(Last) (First) (Middle)

614 MCKINLEY PLACE NE

(Street)

MINNEAPOLIS MN 55413

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIO-TECHNE Corp [ TECH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO

3. Date of Earliest Transaction (Month/Day/Year)
08/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/15/2025		M		4,010	A	$0	131,809	D
Common Stock	08/15/2025		F		1,926	D	$53.6	129,883	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)	$47.6							(1)	08/07/2026	Common Stock	186,068		186,068	D
Stock Options (Right to Buy)	$66.97							(1)	08/05/2027	Common Stock	167,328		167,328	D
Stock Options (Right to Buy)	$120.46							(1)	08/06/2028	Common Stock	40,536		40,536	D
Stock Options (Right to Buy)	$94.52							(3)	08/15/2029	Common Stock	45,220		45,220	D
Performance Restricted Stock Units	(2)							(4)	(4)	Common Stock	13,865		13,865	D
Performance Stock Options (Right to Buy)	$84.61							(4)	08/15/2030	Common Stock	37,314		37,314	D
Stock Options (Right to Buy)	$84.61							(5)	08/15/2030	Common Stock	45,923		45,923	D
Restricted Stock Units	(2)							(6)	(6)	Common Stock	13,159		13,159	D
Performance Restricted Stock Units	(2)							(7)	(7)	Common Stock	24,062		24,062	D
Restricted Stock Units	(2)	08/15/2025		M			4,010	(8)	(8)	Common Stock	4,010	$0	8,021	D
Stock Options (Right to Buy)	$74.91							(9)	08/15/2034	Common Stock	32,417		32,417	D
Restricted Stock Units	(2)							(10)	(10)	Common Stock	34,634		34,634	D
Performance Restricted Stock Units	(2)	08/15/2025		A		29,420		(11)	(11)	Common Stock	29,420	$0	29,420	D
Restricted Stock Units	(2)	08/15/2025		A		14,710		(12)	(12)	Common Stock	14,710	$0	14,710	D
Stock Options (Right to Buy)	$53.6	08/15/2025		A		37,632		(13)	08/15/2035	Common Stock	37,632	$0	37,632	D

Explanation of Responses:

1. Fully exercisable.

2. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock.

3. Options to purchase 11,305 shares vest on each of 8/15/2023, 8/15/2024, 8/15/2025 and 8/15/2026.

4. Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

5. Options to purchase 11,481 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/2027, and options to purchase 11,480 shares vest on 8/15/2026.

6. 13,159 restricted stock units vest on 11/1/2025.

7. Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

8. 4,010 restricted stock units vest on each of 8/15/2025 and 8/15/2026, and 4,011 restricted stock units vest on 8/15/2027.

9. Options to purchase 8,104 shares vest on each of 8/15/2025, 8/15/2026 and 8/15/2027, and options to purchase 8,105 shares vest on 8/15/2028.

10. 11,545 restricted stock units vest on each of 11/1/2025 and 11/1/2026; and 11,544 restricted stock units vest on 11/1/2027.

11. Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

12. 4,903 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 4,904 restricted stock units vest on 8/15/2028.

13. Options to purchase 12,544 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2028.

	/s/ Andrew Nick as Attorney-in-Fact for James Hippel pursuant to Power of Attorney previously filed	08/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did James Hippel report on Form 4 for TECH?

The Form 4 reports a non-cash acquisition/vesting of 4,010 restricted stock units (Code M) and a sale of 1,926 common shares at $53.60 each on 08/15/2025.

How many shares does James Hippel beneficially own after the reported transactions?

The filing states 129,883 shares of common stock beneficially owned following the reported transactions.

What kinds of equity awards does the Form 4 disclose for the CFO of TECH?

The Form 4 discloses stock options with various exercise prices and expirations, restricted stock units, and performance restricted stock units with specified vesting schedules.

Were any options exercised for cash according to the filing?

No exercised-for-cash transactions are reported. The acquisition listed under Code M shows a $0 price, consistent with vesting or similar non-cash event.

Does the filing indicate any performance-based awards?

Yes. The filing lists performance restricted stock units and performance stock options that vest in full or in part if specified performance goals are achieved.